Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.
about
Clinical Translation of Nanomedicine.Development and evaluation of pH-responsive single-walled carbon nanotube-doxorubicin complexes in cancer cells.Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents.Temperature- and pH-responsive smart polymers for gene delivery.Anticancer carrier-linked prodrugs in clinical trials.Biological stimuli and biomolecules in the assembly and manipulation of nanoscale polymeric particles.Recent advances in stealth coating of nanoparticle drug delivery systemsAcid-degradable polymers for drug delivery: a decade of innovation.Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release.Peptide-directed self-assembly of functionalized polymeric nanoparticles part I: design and self-assembly of peptide-copolymer conjugates into nanoparticle fibers and 3D scaffolds.HPMA copolymer conjugates of DOX and mitomycin C for combination therapy: physicochemical characterization, cytotoxic effects, combination index analysis, and anti-tumor efficacy.Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines.Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer.Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and ApplicationsAntibody-targeted polymer-doxorubicin conjugates with pH-controlled activation.
P2860
Q30355939-22ADEF10-BFFD-430E-AFA4-1530F2B6BF09Q34087482-ED26BD32-1738-49BD-B056-266E37E33CE2Q35751371-CFA4CF5A-1FFC-4B29-8801-4DEB552E80F6Q36583719-BEA0815D-DC01-42FE-BBD3-B442D5046ABBQ36861603-48A3F1EC-AED1-4AF4-80A6-B01ADE5DF32FQ37396540-0B8828EC-D860-4520-B442-9ECDBAE8DABBQ37974590-4120E8E5-8937-4AF6-B1CC-3692FDFF1949Q38074172-1DD4A4B3-1A8E-4A0D-B131-4B5D2713C427Q38327563-1CF59698-896B-49A2-8150-7B6E498E0A13Q38626421-D5F283FB-0BB9-44CF-8F3C-A7AB195832E6Q39017174-85F94FB8-1A87-41BA-9943-6209B4878363Q39096548-05AFEB56-3FDC-4BD7-AD9E-752EDC12884DQ39264057-C896F245-9B42-4056-9702-E4DB972A114EQ39445066-24001CA6-96ED-439C-9978-9C5F0C956016Q42175440-D697E5EE-4CF5-4B16-B8DF-E91229551695Q45204007-B050EFBA-441A-4E6F-BA82-808A05AB560F
P2860
Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Doxorubicin bound to a HPMA co ...... limited content of lysosomes.
@en
type
label
Doxorubicin bound to a HPMA co ...... limited content of lysosomes.
@en
prefLabel
Doxorubicin bound to a HPMA co ...... limited content of lysosomes.
@en
P2093
P1476
Doxorubicin bound to a HPMA co ...... limited content of lysosomes.
@en
P2093
M Jelínková
P304
P356
10.1016/S0168-3659(01)00320-0
P407
P577
2001-07-01T00:00:00Z